Behringer K - Search Results

1

Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.

Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert A. Bröckelmann PJ, et al. Among authors: behringer k. J Clin Oncol. 2021 Jan 10;39(2):107-115. doi: 10.1200/JCO.20.00947. Epub 2020 Oct 15. J Clin Oncol. 2021. PMID: 33058716

2

[Modern pharmacotherapy of Hodgkin disease].

Josting A, Behringer K, Engert A, Diehl V. Josting A, et al. Among authors: behringer k. Internist (Berl). 2004 Jan;45(1):93-101. doi: 10.1007/s00108-003-1094-2. Internist (Berl). 2004. PMID: 14735247 Review. German.

3

Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group.

Behringer K, Josting A, Schiller P, Eich HT, Bredenfeld H, Diehl V, Engert A; German Hodgkin Lymphoma Study Group. Behringer K, et al. Ann Oncol. 2004 Jul;15(7):1079-85. doi: 10.1093/annonc/mdh273. Ann Oncol. 2004. PMID: 15205202 Free article.

4

Female fertility after cytotoxic therapy--protection of ovarian function during chemotherapy of malignant and non-malignant diseases.

Mattle V, Behringer K, Engert A, Wildt L. Mattle V, et al. Among authors: behringer k. Eur J Haematol Suppl. 2005 Jul;(66):77-82. doi: 10.1111/j.1600-0609.2005.00459.x. Eur J Haematol Suppl. 2005. PMID: 16007873 Review.

5

Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.

Nogová L, Reineke T, Josting A, Müller-Hermelink HK, Eich HT, Behringer K, Müller RP, Diehl V, Engert A. Nogová L, et al. Among authors: behringer k. Eur J Haematol Suppl. 2005 Jul;(66):106-10. doi: 10.1111/j.1600-0609.2005.00462.x. Eur J Haematol Suppl. 2005. PMID: 16007877

6

Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.

Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A; German Hodgkin Study Group. Klimm B, et al. Among authors: behringer k. J Clin Oncol. 2005 Nov 1;23(31):8003-11. doi: 10.1200/JCO.2005.205.60. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204002 Clinical Trial.

7

Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.

Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A; German Hodgkin's Lymphoma Study Group. Behringer K, et al. J Clin Oncol. 2005 Oct 20;23(30):7555-64. doi: 10.1200/JCO.2005.08.138. J Clin Oncol. 2005. PMID: 16234521

8

[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma].

Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J. Borchmann P, et al. Among authors: behringer k. Pathologe. 2006 Feb;27(1):47-52. doi: 10.1007/s00292-005-0811-0. Pathologe. 2006. PMID: 16369761 German.

9

Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?

Diehl V, Behringer K. Diehl V, et al. Among authors: behringer k. Cancer Invest. 2006 Jun-Jul;24(4):461-5. doi: 10.1080/07357900600705789. Cancer Invest. 2006. PMID: 16777701 Review.

10

German Hodgkin's Lymphoma Study Group trials: lessons from the past and current strategies.

Draube A, Behringer K, Diehl V. Draube A, et al. Among authors: behringer k. Clin Lymphoma Myeloma. 2006 May;6(6):458-68. doi: 10.3816/CLM.2006.n.026. Clin Lymphoma Myeloma. 2006. PMID: 16796776 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters